Vericel Analyst Ratings
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $57
BTIG Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $60
Buy Rating on Vericel: Expanding Market Reach With FDA-Approved MACI Arthro Platform
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $55
TD Cowen Keeps Their Buy Rating on Vericel (VCEL)
Vericel Analyst Ratings
Truist Financial Maintains Vericel(VCEL.US) With Buy Rating
Vericel Corporation: Strong Growth Potential With MACI Product Driving Buy Rating
A Quick Look at Today's Ratings for Vericel(VCEL.US), With a Forecast Between $55 to $60
Vericel Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Vericel (VCEL)
Strong Sales Growth and Promising Pipeline Secure Buy Rating for Vericel
Buy Rating on Vericel: Expanding MACI's Market Potential and Sustaining Top-Line Growth
Truist Lifts Price Target on Vericel to $57 From $56, Maintains Buy Rating
Vericel Analyst Ratings
Vericel Analyst Ratings
Vericel's Strong Q1 Performance and Growth Potential Affirm Buy Rating